Drug offers hope for prostate cancer treatment
Trial results reported by Janssen were so promising that applications will now be made to market the drug worldwide. It means the drug, abiraterone acetate, could soon provide a new lifeline for men with advanced prostate cancer.
A Phase III trial – the last hurdle before a drug reaches the market – was halted early on ethical grounds when it became clear that patients treated with the pill were doing far better than those given a placebo “dummy” drug.
